Dow Jones 30 Stocks SEC Filings — March 19, 2026
Across 50 filings from the USA Dow Jones 30 intelligence stream (primarily smaller caps and blue-chips like UPS, CVS), a mixed sentiment prevails with 12/50 showing positive revenue/EBITDA growth (avg +40% YoY where reported, e.g., SOLV Energy +80% Q4 rev), contrasted by 8 cases of declines (avg -20% YoY rev/ARR) and debt stresses; healthcare/services outperform with 4/6 reporting +20%+ rev growth and margin expansion (e.g., Vericel 74% gross margin, +33% Adj EBITDA). Proxy statements dominate (14/50, mostly neutral, materiality 5/10 avg) signaling annual meeting season with May catalysts, while capital allocation leans defensive via dividends (6 declarations totaling ~$0.40-0.46/share quarterly). M&A activity peaks with 5 pending votes (RYVYL merger 99% in favor but adjourned; Vine Hill SPAC venue change) and deals like Aveanna's $175.5M acquisition. No widespread insider trading signals, but major holders noted in funds (GAMCO 9-10%). Forward guidance bullish for 7 cos (e.g., SOLV $3.72-3.82B 2026 rev +50% implied), building Q2 2026 catalysts; portfolio trend: growth outliers in space/health vs stressed balance sheets elsewhere.